Eccrine Porocarcinoma: A Review of the Literature
暂无分享,去创建一个
K. Liopyris | A. Stratigos | D. Koumaki | S. Gregoriou | A. Tsiogka | Mary Kyriazopoulou | D. Koumaki
[1] F. Tirode,et al. Distinct regulations driving YAP1 expression loss in poroma, porocarcinoma and RB1‐deficient skin carcinoma , 2023, Histopathology.
[2] C. Harwood,et al. Variation in management of porocarcinoma: a 10-year retrospective review of 75 cases across three UK tertiary centres. , 2022, Clinical and experimental dermatology.
[3] H. Ujiie,et al. Diagnosis and Management of Porocarcinoma , 2022, Cancers.
[4] C. Foti,et al. PRAME Immunoexpression in 275 Cutaneous Melanocytic Lesions: A Double Institutional Experience , 2022, Diagnostics.
[5] G. Lembarki,et al. Eccrine porocarcinoma: an extremely rare cutaneous tumor from a radiological point of view – case report and review of the literature , 2022, BJR case reports.
[6] H. Yeung,et al. Incidence and trends of cutaneous adnexal tumors in the United States in 2000-2018: A population-based study. , 2022, Journal of the American Academy of Dermatology.
[7] Athanasios Korogiannos,et al. Dermatoscopic Features of a Metastatic Eccrine Porocarcinoma Arising on Lymphedema , 2022, Dermatology practical & conceptual.
[8] D. Kalbermatten,et al. Head and Neck Porocarcinoma: SEER Analysis of Epidemiology and Survival , 2022, Journal of clinical medicine.
[9] V. Koljonen,et al. UV-induced local immunosuppression in the tumour microenvironment of eccrine porocarcinoma and poroma , 2022, Scientific Reports.
[10] A. Di Stefani,et al. The role of postoperative radiotherapy in eccrine porocarcinoma: a multidisciplinary systematic review. , 2022, European review for medical and pharmacological sciences.
[11] S. Vernon,et al. Porocarcinoma: a review , 2022, Clinical and experimental dermatology.
[12] M. Vinogradov,et al. Metastatic Porocarcinoma Effectively Managed by Pembrolizumab , 2021, Cureus.
[13] Jingxiang Huang,et al. Unusual Presentations of Eccrine Porocarcinomas , 2021, Skin Appendage Disorders.
[14] V. Koljonen,et al. Merkel cell polyomavirus is a passenger virus in both poroma and porocarcinoma , 2021, Journal of cutaneous pathology.
[15] S. Fröhling,et al. High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma * , 2021, The British journal of dermatology.
[16] B. Hutter,et al. Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies , 2021, Cancer Gene Therapy.
[17] G. Telang,et al. Clear Cell Differentiation in Eccrine Porocarcinoma as a High-Risk Feature: Epidemiologic and Pathologic Features of Eccrine Porocarcinoma in a Single-Center Case Series , 2021, The American Journal of dermatopathology.
[18] J. Swensen,et al. Poroid adnexal skin tumors with YAP1 fusions exhibit similar histopathologic features: A series of six YAP1‐rearranged adnexal skin tumors , 2021, Journal of cutaneous pathology.
[19] T. Sugino,et al. Comparison of Immunohistochemical Expression of Cytokeratin 19, c-KIT, BerEP4, GATA3, and NUTM1 Between Porocarcinoma and Squamous Cell Carcinoma , 2021, The American Journal of dermatopathology.
[20] V. Koljonen,et al. Malignant Eccrine Porocarcinoma in Finland During 2007 to 2017 , 2020, Acta dermato-venereologica.
[21] K. Patel,et al. Surgical management and lymph-node biopsy of rare malignant cutaneous adnexal carcinomas: a population-based analysis of 7591 patients , 2020, Archives of Dermatological Research.
[22] K. Moon,et al. Eccrine Porocarcinoma: A Multicenter Retrospective Study with Review of the Literatures Reported in Korea , 2020, Annals of dermatology.
[23] R. Seemann,et al. Eccrine porocarcinoma of the head and neck: Meta‐analysis of 120 cases , 2020, Head & neck.
[24] F. Samie,et al. Demographics and outcomes of eccrine porocarcinoma: results from the National Cancer Database , 2020, The British journal of dermatology.
[25] V. Bataille,et al. Metastatic porocarcinoma achieving complete radiological and clinical response with pembrolizumab , 2019, BMJ Case Reports.
[26] Rajiv M. Patel,et al. Altered Rb, p16, and p53 expression is specific for porocarcinoma relative to poroma , 2019, Journal of cutaneous pathology.
[27] K. Tsuta,et al. Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma. , 2019, The Journal of clinical investigation.
[28] T. Sugai,et al. Evaluation of Sentinel Lymph Node Biopsy for Eccrine Porocarcinoma. , 2019, Acta dermato-venereologica.
[29] D. Greenberg,et al. Eccrine Porocarcinoma of the Skin is Rising in Incidence in the East of England. , 2018, Acta dermato-venereologica.
[30] A. Wysong,et al. Eccrine Porocarcinoma: New Insights and a Systematic Review of the Literature , 2018, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].
[31] C. Paul,et al. Complete response of a metastatic porocarcinoma treated with paclitaxel, cetuximab and radiotherapy. , 2017, European journal of cancer.
[32] P. Schirmacher,et al. Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas. , 2017, Pathology.
[33] F. Kakamad,et al. Porocarcinoma; presentation and management, a meta-analysis of 453 cases , 2017, Annals of medicine and surgery.
[34] P. Mendes-Bastos,et al. Dermoscopic and reflectance confocal microscopic presentation of relapsing eccrine porocarcinoma. , 2017, Journal of the American Academy of Dermatology.
[35] A. Weaver,et al. Incidence and Clinical Features of Rare Cutaneous Malignancies in Olmsted County, Minnesota, 2000 to 2010 , 2017, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].
[36] I. Nordman,et al. Metastatic Eccrine Porocarcinoma: A Rare Case of Successful Treatment , 2016, Case Reports in Oncology.
[37] M. Camilleri,et al. Treatment of Porocarcinoma With Mohs Micrographic Surgery: The Mayo Clinic Experience , 2016, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].
[38] S. Tomlins,et al. Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations. , 2016, Human pathology.
[39] K. Chanprapaph,et al. Eccrine Poroma Arising within Nevus Sebaceous , 2016, Case Reports in Dermatology.
[40] T. Hirose,et al. CD117 (KIT) is a useful immunohistochemical marker for differentiating porocarcinoma from squamous cell carcinoma , 2016, Journal of cutaneous pathology.
[41] E. Guevara-Gutiérrez,et al. Eccrine porocarcinoma: epidemiologic and histopathologic characteristics , 2015, International journal of dermatology.
[42] S. Aiba,et al. Successful Treatment of Eccrine Porocarcinoma Metastasized to a Cervical Lymph Node with CyberKnife Radiosurgery , 2014, Case Reports in Dermatology.
[43] L. Thomas,et al. [Primary eccrine porocarcinoma: a clinicopathological study of 50 cases]. , 2014, Annales de dermatologie et de venereologie.
[44] A. Maker,et al. Survival after resection of cutaneous adnexal carcinomas with eccrine differentiation: Risk factors and trends in outcomes , 2013, Journal of surgical oncology.
[45] J. A. van der Hage,et al. Increasing incidence and survival of a rare skin cancer in the Netherlands. A population‐based study of 2,220 cases of skin adnexal carcinoma , 2013, Journal of surgical oncology.
[46] A. Iafrate,et al. Apocrine-Eccrine Carcinomas: Molecular and Immunohistochemical Analyses , 2012, PloS one.
[47] T. Jouary,et al. Factors in the surgical management of primary eccrine porocarcinoma: prognostic histological factors can guide the surgical procedure , 2011, The British journal of dermatology.
[48] S. Martinez,et al. Rare tumors through the looking glass: an examination of malignant cutaneous adnexal tumors. , 2011, Archives of dermatology.
[49] C. Cockerell,et al. The New Seventh Edition American Joint Committee on Cancer Staging of Cutaneous Non-Melanoma Skin Cancer , 2011, American journal of clinical dermatology.
[50] T. Mitsuishi,et al. Pigmented poroid neoplasm mimicking nodular melanoma , 2010, The Journal of dermatology.
[51] S. Devesa,et al. Cutaneous appendageal carcinoma incidence and survival patterns in the United States: a population-based study. , 2010, Archives of dermatology.
[52] T. Ruzicka,et al. Eccrine Porocarcinoma of the Head: An Important Differential Diagnosis in the Elderly Patient , 2008, Dermatology.
[53] H. Koga,et al. Eccrine porocarcinoma: Clinical and pathological studies of 12 cases , 2007, The Journal of dermatology.
[54] H. Kittler,et al. Sentinel node status in melanoma patients is not predicitive for overall survival upon multivariate analysis , 2005, British Journal of Cancer.
[55] B. Balda,et al. Metastasising porocarcinoma following exposure to poison gas , 2002, The Lancet.
[56] P. H. Mckee,et al. Eccrine Porocarcinoma (Malignant Eccrine Poroma): A Clinicopathologic Study of 69 Cases , 2001, The American journal of surgical pathology.
[57] C. Hees,et al. Malignant eccrine poroma in a patient with Rothmiund‐Thomson syndrome , 1996, The British journal of dermatology.
[58] Kunio Inoue,et al. An immunohistologic study on eccrine gland carcinoma. , 1989, Journal of the American Academy of Dermatology.
[59] D. Lowe,et al. Malignant eccrine poroma: a study of twenty‐seven cases , 1982, The British journal of dermatology.
[60] Y. Mishima,et al. Oncogenic differentiation of the intraepidermal eccrine sweat duct: eccrine poroma, poroepithelioma and porocarcinoma. , 1969, Dermatologica.
[61] H. Pinkus,et al. EPIDERMOTROPIC ECCRINE CARCINOMA. A CASE COMBINING FEATURES OF ECCRINE POROMA AND PAGET'S DERMATOSIS. , 1963, Archives of dermatology.